Shares of Curevac NV tanked more than 50% in the extended session Wednesday after the pharma company said its trial COVID-19 vaccine showed an efficacy of 47% against the illness.
Curevac’s
CVAC,
-3.47%
messenger RNA-based vaccine would compete with similar vaccines from Pfizer and BioNTech as well as Moderna, which have shown efficacy above 90% and have already been distributed to millions of people across the globe.